FDA records Novo Nordisk notice that Saxenda will be discontinued in January 2027

Novo Nordisk has told the FDA that Saxenda, its daily liraglutide injection for weight management, will be discontinued. An entry posted August 25, 2026 in the FDA's drug discontinuation database lists "Saxenda, Injection, 6 mg/1 mL (NDC 0169-2800-15)" with the note: "Product will be available until discontinuation in January 2027; Discontinuation of the manufacture of the drug" ^[1].

The same date brought a revision to FDA's current shortage listing for liraglutide injection. There, Novo Nordisk's Saxenda is marked "Limited Availability" with the same January 2027 note and a link to the discontinuation record ^[2]. Two Victoza package sizes — liraglutide for type 2 diabetes, NDCs 0169-4060-12 and 0169-4060-13 — are also listed as "Limited Availability," with the reason given as "Delay in shipping of the drug" and an estimated shortage duration of "TBD" ^[2].

Novo Nordisk's Saxenda website carries a discontinuation notice that adds detail the FDA record does not. It says last shipments to wholesalers will take place in late January 2027, and that the company made "the strategic portfolio decision to discontinue the brand" because "alternative medicines have become available and the number of patients using Saxenda has continued to decline." The notice states the decision "is not the result of any safety or quality-related concerns" and points patients to Novo Nordisk's Customer Care Center at 1-800-727-6500 ^[4].

What the databases show

Liraglutide injection has been on FDA's shortage list since July 18, 2023 ^[2]. The current listing is a mixed picture. Hikma Pharmaceuticals shows two liraglutide NDCs as "Available" as of a September 3, 2026 revision, and Meitheal Pharmaceuticals shows two as "Available" as of August 27, 2026 ^[2]. Under Novo Nordisk's entry, two additional liraglutide presentations (NDCs 0480-3667-20 and 0480-3667-22, noted as "Distributed by Teva") are listed as "Available" ^[2].

Separately, Teva Pharmaceuticals USA told FDA on May 14, 2026 that it was discontinuing manufacture of its own liraglutide injection, NDC 0480-7250-46 ^[1]. FDA's openFDA data mirrors that record, listing it with status "To Be Discontinued" and an application number of ANDA214568 ^[5]. The openFDA shortage dataset was last updated September 14, 2026 and returns 11 total liraglutide records ^[5].

As of that same date, no matching announcement about the Saxenda discontinuation appeared in Novo Nordisk's US news archive, whose most recent posted items were an August 11, 2026 press release on once-weekly insulin Awiqli and an August 4, 2026 financial report ^[3]. In other words, the company put a notice on the Saxenda product site ^[4] and filed with FDA ^[1], but did not issue a press release picked up in its US archive ^[3].

Why it matters for patients

Saxenda is liraglutide, an older, once-daily GLP-1 injection approved for adults with obesity or with overweight plus weight-related medical problems, and for children aged 12 to 17 who weigh more than 132 pounds and have obesity ^[4]. People currently filling Saxenda prescriptions now have a defined end date: FDA's record says the product is available until discontinuation in January 2027 ^[1], and the company's notice says last shipments to wholesalers occur in late January 2027 ^[4]. Supply at the pharmacy level after that is not addressed in either source, so how long remaining stock circulates is not yet known.

The Victoza listings are a separate issue. Both Victoza package sizes are flagged as limited because of a shipping delay, with no end date given ^[2]. FDA's "Limited Availability" label means some product is moving, but the database does not say how much or which pharmacies are affected.

Generic and other-brand liraglutide remains on the market according to FDA's listing, with Hikma and Meitheal presentations shown as available ^[2]. Whether any of those are interchangeable substitutes for a specific Saxenda or Victoza prescription depends on the product's approved uses and is a question for a prescriber or pharmacist; Novo Nordisk's notice says to consult a health care provider about alternative treatment options ^[4].

What happens next

The key dated milestone is January 2027, when FDA's record says Saxenda supply ends ^[1] and the company says wholesaler shipments stop ^[4]. FDA has not posted an estimated resolution date for the Victoza shipping delay ^[2]. Novo Nordisk has not, as of September 14, 2026, published a broader announcement explaining the timeline in its US news archive ^[3].